PLRX News and Press, Pliant Therapeutics Inc. From 05/21/25

SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held f...

Redwire Corporation (RDW) is expected to report $-0.2 for Q1 2025 Organigram Global Inc. (OGI) is expected to report $-0.03 for Q2 2025 Inter & Co. Inc. (INTR) is expected to report $0.12 for Q1 2025 Pervasip Corp (PVSP) is expected to report for quarter end 2025-02-28 Maui La...

2025-05-08 17:58:08 ET More on Pliant Therapeutics Pliant Therapeutics: An Activist On Deck Pliant Therapeutics: Strange Volatility Pliant Therapeutics to trim about 45% of workforce Pliant downgraded at Stifel on bexotegrast trial discontinuation See...

Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials SOUTH SAN FRANCISCO...

National Health Investors Inc. (NHI) is expected to report $1.13 for Q1 2025 Palomar Holdings Inc. (PLMR) is expected to report $1.45 for Q1 2025 Weave Communications Inc. (WEAV) is expected to report $-0.11 for Q1 2025 First National Bank Alaska (FBAK) is expected to report for Q1 20...

2025-05-04 18:48:27 ET Pliant Therapeutics, Inc. (PLRX) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 1.92%. The average open to low on the day of earnings was -9.65%. The average open...

2025-05-04 18:43:28 ET Pliant Therapeutics, Inc. (PLRX) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in PLRX stock price following earnings has averaged ±1.82% , with a median of 0.72%...

2025-05-02 10:27:18 ET More on Pliant Therapeutics Pliant Therapeutics: An Activist On Deck Pliant Therapeutics: Strange Volatility Pliant downgraded at Stifel on bexotegrast trial discontinuation Pliant dives 49% as it abandons phase 2 trial of bexotegrast f...

-  Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials -  Pliant will reduce its current workforce by approximately 45% -  Closing activities for BEACON-IPF trial ongoing; topline data expected in t...

SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California ...